A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This single arm study will evaluate the safety profile of Xeloda as monotherapy for adjuvant
treatment of colon cancer. All patients will receive Xeloda 1250mg/m2 p.o. twice daily as
intermittent treatment (3 week cycles consisting of 2 weeks of treatment followed by 1 week
without treatment). The anticipated time on study treatment is 3-12 months, and the target
sample size is 500+ individuals.